EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema: 2-Year Results from IDEAL, a Prospective German Observational Study

Focke Ziemssen, Hakan Kaymak, Michaela Siebert, Ramin Khoramnia

Ophthalmologica · 14.04.2026 · 1-11

DOI: 10.1159/000551863 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Ophthalmologica, online erschienen am 14.04.2026. Verfasst von Focke Ziemssen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Leipzig, Leipzig, Germany, focke.ziemssen@medizin.uni-leipzig.de. Hauptthemen laut MEDLINE: Fluocinolone Acetonide, Macular Edema, Diabetic Retinopathy, Visual Acuity. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The prospective, observational IDEAL study evaluated the effectiveness and safety of the long-acting fluocinolone acetonide (FAc) implant in patients with chronic diabetic macular edema (DME) and examined the influence of various baseline factors on treatment success.

Methods

Patients with persistent DME despite prior treatment with available therapies who received FAc implant were included from 35 ophthalmological centers in Germany and monitored for up to 24 months. Demographic and clinical data, including disease duration, previous treatment, best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse events were recorded at routine visits and analyzed descriptively, also in predefined groups.

Results

Overall, 214 eyes from 185 patients (57% male) with a mean (SD) age of 66.2 (9.7) years were followed up for a mean (SD) of 21.53 (6.49) months. Functional and anatomical improvements occurred rapidly within 1 week after FAc injection and were sustained over 24 months in these previously intensively treated eyes (72.9% laser treatment, 79.9% intravitreal therapy with dexamethasone and/or anti-VEGF inhibitors, 28.9% vitrectomy). Mean BCVA increased from 55.8 (18.4) letters at baseline to 60.9 (19.0) letters at 24 months, with comparable results across subgroups defined by baseline characteristics. Eyes with fewer than two prior dexamethasone injections showed a more pronounced CMT reduction. In a subset with early follow-up, greater CMT reduction at week 1 was strongly associated with greater CMT reduction at month 1. Mean IOP in the total cohort increased from 15.3 ± 3.3 mm Hg to 17.4 ± 4.8 mm Hg within 9 months and returned to 16.7 ± 5.0 by month 24. IOP lowering was required in 35.5% of eyes (topical medication), and 4.6% underwent IOP-lowering surgery.

Conclusion

The IDEAL observational study demonstrated a rapid onset of effect and reaffirmed the long-term efficacy and safety of the FAc implant in a large cohort of patients with persistent DME despite extensive prior treatment, thus underlining the high medical need of this treatment option for DME patients insufficiently responding to other therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluocinolone AcetonideMacular EdemaDiabetic RetinopathyVisual AcuityMacula LuteaHumansProspective StudiesMaleDrug ImplantsFemaleGlucocorticoidsIntravitreal InjectionsFollow-Up StudiesAgedTreatment OutcomeTomography, Optical CoherenceGermanyTime FactorsIntraocular PressureMiddle Aged

Stichwörter der Autor:innen

Diabetic macular edemaIntravitreal fluocinolone acetonidePersistent diabetic macular edema

Substanzen

Fluocinolone AcetonideDrug ImplantsGlucocorticoids

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Leipzig, Leipzig, Germany, focke.ziemssen@medizin.uni-leipzig.de.
  • Center for Ophthalmology, Eberhard Karl University Tuebingen, Tuebingen, Germany, focke.ziemssen@medizin.uni-leipzig.de.
  • Macular Retina Center Düsseldorf, Düsseldorf, Germany.
  • Alimera Sciences Ophthalmologie GmbH, Berlin, Germany.
  • Department of Ophthalmology, University of Heidelberg, Heidelberg, Germany.
  • Department of Ophthalmology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.

Zitieren

APA

Ziemssen, F., Kaymak, H., Siebert, M., & Khoramnia, R. (2026). Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema: 2-Year Results from IDEAL, a Prospective German Observational Study. Ophthalmologica, 1-11. https://doi.org/10.1159/000551863

Vancouver

Ziemssen F, Kaymak H, Siebert M, Khoramnia R. Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema: 2-Year Results from IDEAL, a Prospective German Observational Study. Ophthalmologica. 2026:1-11. doi:10.1159/000551863

BibTeX
@article{Ziemssen2026,
  author = {Ziemssen, Focke and Kaymak, Hakan and Siebert, Michaela and Khoramnia, Ramin},
  title = {Intravitreal Fluocinolone Acetonide Implant for Diabetic Macular Edema: 2-Year Results from IDEAL, a Prospective German Observational Study},
  journal = {Ophthalmologica},
  year = {2026},
  pages = {1--11},
  doi = {10.1159/000551863}
}
Kostenlos starten →